Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Cefsulodine sodium |
EINECS | 257-692-4 |
CAS No. | 52152-93-9 | Density | N/A |
PSA | 227.39000 | LogP | -0.12670 |
Solubility | water: 50 mg/mL, clear, light yellow | Melting Point |
175 °C |
Formula | C22H19N4NaO8S2 | Boiling Point | N/A |
Molecular Weight | 554.537 | Flash Point | N/A |
Transport Information | N/A | Appearance | White to pale yellow crystalline powder |
Safety | 22-26-36/37-45-36 | Risk Codes | 36/37/38-42/43-20/21/22 |
Molecular Structure | Hazard Symbols | Xi,Xn | |
Synonyms |
Pyridinium,4-(aminocarbonyl)-1-[[(6R,7R)-2-carboxy-8-oxo-7-[[(2R)-phenylsulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-,inner salt, monosodium salt (9CI);7-(D-a-Sulfophenylacetamido)ceph-3-em-3-(4'-carbamoylpyridinium)methyl-4-carboxylatesodium salt;Abbot 46811;CGP 7174E;Cefomonil;Cefsulodin sodium;D-(-)-SCE-129;Monaspor;Monosodium cefsulodin;Pseudocef;Pseudomonil;Pyocefal;Pyridinium,4-(aminocarbonyl)-1-[[2-carboxy-8-oxo-7-[(phenylsulfoacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-,inner salt, monosodium salt, [6R-[6a,7b(R*)]]-;SCE 129;Sulcephalosporin;Takesulin;Tilmapor;Ulfar; |
Article Data | 3 |
Molecular structure of Cefsulodine sodium (CAS NO.52152-93-9) is:
Product Name: Cefsulodine sodium
CAS Registry Number: 52152-93-9
IUPAC Name: sodium (6R,7R)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfonatoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Molecular Weight: 554.52803 [g/mol]
Molecular Formula: C22H19N4NaO8S2
H-Bond Donor: 2
H-Bond Acceptor: 8
EINECS: 257-692-4
Melting Point: 175 °C
Storage temp.: 2-8 °C
Solubility: H2O: 50 mg/mL, clear, light yellow
Product Categories: A - KResearch Essentials;Antibacterial;Antibiotics A to;Antibiotics A-FAntibiotics;AntibioticsAntibiotics;Chemical Structure Class;Core Bioreagents;Interferes with Cell Wall SynthesisAntibiotics;Mechanism of Action;Penicillins and Cephalosporins (beta-Lactams);Spectrum of Activity
Cefsulodine sodium (CAS NO.52152-93-9) is a narrow-spectrum cephalosporin with marked in vitro activity against clinical isolates of Pseudomonas aeruginosa.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | oral | > 15gm/kg (15000mg/kg) | Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983. | |
dog | LD50 | parenteral | > 2500mg/kg (2500mg/kg) | Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983. | |
hamster | LD50 | intraperitoneal | > 4gm/kg (4000mg/kg) | Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983. | |
hamster | LD50 | oral | > 15gm/kg (15000mg/kg) | Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983. | |
hamster | LD50 | parenteral | > 2500mg/kg (2500mg/kg) | Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983. | |
mouse | LD50 | intramuscular | 3800mg/kg (3800mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981. | |
mouse | LD50 | intraperitoneal | 6350mg/kg (6350mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981. | |
mouse | LD50 | intravenous | 3780mg/kg (3780mg/kg) | Drugs in Japan Vol. 6, Pg. 412, 1982. | |
mouse | LD50 | oral | > 15gm/kg (15000mg/kg) | Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983. | |
mouse | LD50 | parenteral | > 2500mg/kg (2500mg/kg) | Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983. | |
mouse | LD50 | subcutaneous | 6940mg/kg (6940mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981. | |
rabbit | LD50 | oral | > 15gm/kg (15000mg/kg) | Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983. | |
rabbit | LD50 | parenteral | > 2500mg/kg (2500mg/kg) | Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983. | |
rat | LD50 | intramuscular | 5530mg/kg (5530mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981. | |
rat | LD50 | intraperitoneal | 3030mg/kg (3030mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981. | |
rat | LD50 | intravenous | 3030ug/kg (3.03mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 23, Pg. 439, 1981. | |
rat | LD50 | oral | > 15gm/kg (15000mg/kg) | Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983. | |
rat | LD50 | parenteral | > 2500mg/kg (2500mg/kg) | Lyon Pharmaceutique. Vol. 34, Pg. 343, 1983. | |
rat | LD50 | subcutaneous | 5550mg/kg (5550mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 668, 1981. |
Hazard Codes: Xi,Xn
Risk Statements: 36/37/38-42/43-20/21/22
36/37/38: Cefsulodine sodium (52152-93-9) is irritating to eyes, respiratory system and skin
42/43: May cause sensitization by inhalation and skin contact
20/21/22: Cefsulodine sodium (52152-93-9) is harmful by inhalation, in contact with skin and if swallowed
Safety Statements: 22-26-36/37-45
36/37: Wear suitable protective clothing and gloves
45: In case of accident or if you feel unwell, seek medical advice immediately (show label where possible)
22: Do not breathe dust
26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice
WGK Germany: 2
RTECS: UU1785000
Cefsulodine sodium , its cas register number is 52152-93-9. It also can be called Sodium (6R,7R)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfonatoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate ; Hydrogen (6R-(6alpha,7beta(R*)))-4-carbamoyl-1-((2-carboxylato-8-oxo-7-(phenylsulphonatoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium, monosodium salt ; Pyridinium, 4-(aminocarbonyl)-1-(((6R,7R)-2-carboxy-8-oxo-7-(((2R)-2-phenyl-2-sulfoacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, sodium salt (1:1) ; Pyridinium, 4-(aminocarbonyl)-1-(((6R,7R)-2-carboxy-8-oxo-7-(((2R)-phenylsulfoacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, monosodium salt ; Pyridinium, 4-(aminocarbonyl)-1-((2-carboxy-8-oxo-7-((phenylsulfoacetyl)amino)-5-thio-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, hydroxide, inner salt, monosodium salt, (6R-(6-alpha,7-beta(R*)))- .